ERBB2 and breast cancer: Clinical trials support this notion; the DESTINY-Breast04 and Daisy studies showed favorable outcomes using DS8201 in treating patients with low HER2-expressing breast cancer and even in those with HER2–0 breast cancer (47, 48).